MedTrace Logo

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

NCT06174220 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-03-12

No results posted yet for this study

Summary

The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.

Conditions

  • Arrhythmogenic Cardiomyopathy
  • Arrhythmogenic Right Ventricular Cardiomyopathy

Interventions

DRUG

Tideglusib

Tideglusib 1g po daily

DRUG

Placebo

Matching placebo 1g po daily

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Canadian SADS

    collaborator UNKNOWN

  • AMO Pharma Limited

    collaborator INDUSTRY

  • Hearts in Rhythm Organization (HiRO)

    collaborator UNKNOWN

  • Population Health Research Institute

    collaborator OTHER

  • Hamilton Health Sciences Corporation

    lead OTHER

Principal Investigators

  • Jason D Roberts, MD MAS · McMaster University and Population Health Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-21
Primary Completion
2027-02-01
Completion
2027-07-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06174220 on ClinicalTrials.gov